Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer

Ziad Bakouny ^{1,*}, Chris Labaki ^{1,*}, Punita Grover ^{2,*}, Joy Awosika ², Shuchi Gulati ², Chih-Yuan Hsu ³, Mehmet A. Bilen ⁴, Omar E. Eton ⁵, Leslie A. Fecher ⁶, Clara Hwang ⁷, Hina Khan ⁸, Rana R. McKay ⁹, Erika Ruíz-García ^{10,} Lisa B. Weissmann¹¹, Michael A. Thompson¹², Dimpy P. Shah¹³, Jeremy L. Warner³, Yu Shyr³, Toni K. Choueiri^{1,†}, Trisha M. Wise-Draper^{2,†} Email address: ziad_elbakouny@dfci.harvard.edu ; chris_labaki@dfci.harvard.edu ; groverpt@mail.uc.edu – Twitter: @ZiadBakouny @Chrislabaki1 @punita_grover

BACKGROUND

- Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation.
- Patients with cancer treated with immunotherapy (IO) and those with immunosuppression may have higher rates of cytokine storm due to immune dysregulation.
- We sought to evaluate the association between baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer, based on data from the COVID-19 and Cancer Consortium (CCC19).

METHODS

- We conducted a registry-based retrospective study on patients reported to the CCC19 registry from March 2020 to May 2022.
- Baseline immunosuppression status was defined as recent history of stem cell transplant, or receipt of standard immunosuppressive medications, corticosteroids, bruton kinase inhibitors, or anti-CD20, prior to COVID-19.
- IO was defined as receipt of PD-(L)1 and/or CTLA-4 inhibitors, BiTE or CAR T-cell therapies within 3 months of COVID-19 diagnosis. Non-IO therapy was defined as receipt of cytotoxic chemotherapy, targeted therapies or endocrine therapies within 3 months of COVID-19 diagnosis.
- The primary outcome was a five-level ordinal scale of COVID-19 severity. The secondary outcome was the occurrence of cytokine storm, defined as biological and clinical evidence of severe inflammation, with end-organ dysfunction.
- We conducted a multivariable logistic regression balanced for covariate distributions through inverse probability of treatment weighting (IPTW), and adjusted for demographic and clinical variables. As baseline immunosuppression might modify the effect anti-cancer systemic therapies, we included the interaction terms of cancer treatment and immunosuppression in the regression models. When the interaction terms were significant, additional subgroup analyses were computed to clarify the effect of the exposures in each stratum.

Treatment group (versus none) Non-IO <u>Age (every 10-year increase)</u> Sex (versus Female) Race (versus Non-Hispanic White) Hispanic Non-Hispanic Black Obesity status (versus not obese) Smoking status (versus never smoker) Comorbidities (present versus absent) Cardiovascular Pulmonary Renal Diabetes mellitus ECOG PS (versus 0) Unknown Solid tumors Hematological Thoracic Cancer status (versus remission or NED) Active and responding Active and stable Active and progressing Unknown Country of residence (US versus not) Sept - Dec 2020 Jan - Apr 2021 May - Aug 202 Sept - Dec 2021 <u>Jan - Apr 2022</u> Vaccination status (versus none)

Figure 1: Forest plots of adjusted odds ratios (aORs) for COVID-19 severity, stratified by immunosuppression status.




In patients with cancer and COVID-19, administration of systemic anti-cancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm.



Dana-Farber Cancer Institute





Patients with cancer with baseline immunosuppression and COVID-19 may experience worse outcomes when treated with IO or non-IO systemic anticancer therapy.

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2. Division of Hematology/Oncology, University of Cincinnati Cancer Center, Cincinnati, OH; 3. Vanderbilt University, Nashville, TN; 4. Winship Cancer Institute, Emory University, Atlanta, GA; 5. Hartford Healthcare Cancer Institute, Hartford, CT ; 6. COVID-19 & Cancer Consortium University of Michigan Rogel Cancer Center, Ann Arbor, MI; 7. Henry Ford Cancer Institute, Detroit, MI; 8. Brown University and Lifespan Cancer Institute, Providence, RI; . Moores Cancer Center, UCSD, San Diego, CA; 10. Instituto Nacional de Cancerologia, Mexico; 11. Mt. Auburn Hospital, Boston, MA; 12. Aurora Cancer Center, Advocate Aurora Health, Milwaukee, WI; 13. Mays Cancer Center, UT Health, San Antonio, TX

RESULTS

- A total of **12,046 patients** were included. Median age was 65 years (interquartile range: 54-74 years).
- Overall, 5.0% (n=599) of patients were in the IO group, while 35.9% (n=4,327) received non-IO therapies and 59.1% (n=7,120) were not anti-neoplastic regimen administered any (untreated group).
- In the IO group, 23% (n=138) of patients died, compared to 20% (n=856) in the non-IO group, and 16% (n=1,124) in the untreated group. The raw incidence of cytokine storm was comparable across all groups at 12% with n=68, 533 and 860 for the IO, non-IO, and untreated groups, respectively.
- In the regression analysis, the interaction term of IO (vs. untreated) group and immunosuppression presented a strong, but non-significant trend towards worse clinical outcomes (aOR: 3.12; 0.93-10.47), and was significantly 95%CI: associated with the development of a cytokine storm (aOR: 6.36; 95%CI: 1.56-25.95). The interaction term of non-IO (vs. untreated) group and baseline immunosuppression was significantly associated with more severe COVID-19 (aOR: 1.44; 95%CI: 1.08-1.90) and a higher risk of cytokine storm (aOR: 1.69; 95%CI: 1.02-2.80).
- Based on these results, multivariate analyses stratified by immunosuppression status, both the IO (vs. untreated) and non-IO (vs. untreated) groups were associated with worse COVID-19 outcomes in the context of pre-existing **immunosuppression** (aOR: 3.33; 95%CI: 1.38-8.01 and aOR: 1.79; 95%CI: 1.36-2.35, respectively) (Figure 1). Additionally, similar findings were observed in relation to the development of cytokine storm.